E-18 Corp. Announces Availability of New Investor Fact Sheet
MINNEAPOLIS-(Business Wire)-September 29, 2009 - E-18 Corp. (OTCBB: ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), announces the availability of a new online Investor Fact Sheet.
“As part of our stated goal in keeping investors informed with the latest developments at the Company, we are releasing our new fact sheet, which will be frequently updated,” said Dr. John Salstrom, President and CEO of Protectus Medical Devices. “Billions of dollars are spent every year on needlestick injuries, in addition to hundreds of lives that are put at risk due to the inadvertent transmission of blood-borne disease. Our innovative self-sheathing devices have the potential to dramatically reduce needlestick injuries for medical professionals worldwide, in addition to being the only technology that meets all U.S. Federal Government and OSHA mandates.”
The Investor Fact Sheet provides a concise overview of the Company’s cutting-edge, self-sheathing Protectus Safety Syringe and its growth potential in the healthcare industry. The Investor Fact Sheet is a great resource for loyal shareholders and prospective investors alike.
The Fact Sheet is available at: www.trilogy-capital.com/autoir/eten_autoir.html
About E-18 Corp.
E-18 Corp., through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices, develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-Sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
